A recent survey of 103 American gastroenterologists suggests that Stelara (ustekinumab) has gained in popularity as a treatment for Crohn's disease (CD), with significant gains projected for the rest of the year.
The report, authored by market intelligence firm Spherix Global Insights, provides some indication of prescribing patterns in the management of the disease, a chronic and painful condition which affects millions.
The survey found that nearly 60% of respondents are current Stelara prescribers, a figure anticipated to increase to 77% in the next six months.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze